TIDMTRLS
RNS Number : 6495P
Trellus Health PLC
13 February 2023
Trellus Health plc
("Trellus Health" or the "Company")
Trellus IBD program to be offered through New York Medicaid
Health Plan
Demonstration project in partnership with New York State health
insurer with over 1.8 million members
LONDON, U.K. AND NEW YORK, U.S. (13 February 2023): Trellus
Health plc (AIM: TRLS), which is commercializing a scientifically
validated, personalized resilience-driven self-management solution
for chronic health conditions at their intersection with mental
health, announces that the Trellus Resilience Training and
Self-Management Solution for Inflammatory Bowel Disease (the
"Trellus IBD program") will be made available under an initial
demonstration project with a New York-based health insurance
company (the "Partner") with more than 1.8 million members.
The Trellus IBD program is designed to enable IBD patients to
take charge of their health needs, access behavioral and emotional
support in between office visits, and ultimately to improve
outcomes. The use of digital tools for self-care and ongoing
coaching under the Trellus IBD program aligns strongly with the
Partner's goal of providing value-driven, optimized care that is
available with equal opportunity to all.
Under the terms of the agreement, the Trellus IBD program is now
included as a health plan benefit to certain Partner members under
its Medicaid managed care plan, to coordinate and deliver
personalized behavioral, emotional and nutritional support for the
Partner's Medicaid IBD patients remotely via digital solutions, and
provide access to an expert resilience team via telehealth . The
Partner will pay for such members' enrolment and participation in
the Trellus IBD Program, with a targeted maximum enrolment of 50
patients. The agreement will run for an initial 12-month term and
can be extended by mutual agreement, with patient enrolment to
begin imminently.
This partnership is the culmination of the final contracting
phase with a New York Medicaid health plan which was referred to in
the Company's interim results release issued on 30 September 2022,
and represents further execution of Trellus Health's strategy to
expand access to its self-management solution through both its
Direct-to-Consumer ("D2C") and Business-to-Business-to-Consumer
("B2B2C") models. This B2B2C partnership will provide Trellus
Health with further data to strengthen the evidence base of the
ability of the Trellus IBD program to provide improvements in
outcomes and on reductions in the cost of caring for GI patients.
Meeting these shared core objectives is expected to support the
wider rollout of the Trellus IBD solution.
Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health,
said: "I am delighted to sign this B2B2C agreement with this New
York State-based health insurer to offer the Trellus IBD program to
up to 50 of its members over a 12-month period. Access to the
Trellus IBD program will enable the insurer to empower its members
to learn to self-manage their chronic conditions with confidence,
and improve health outcomes at a significantly lower cost. We look
forward to reviewing the data from this initial 12-month term,
which will further strengthen our evidence base as we continue
discussions with other regional and national health plans,
employers, health systems, GI provider networks and pharmaceutical
companies.
"We look forward to working with this Health Plan to evaluate
further how the Trellus IBD program can achieve better health
outcomes, and how enhanced condition management and quality of life
measures can be supported by improvements in resilience using our
approach."
For further information please contact:
Trellus Health plc www.trellushealth.com
Dr. Marla Dubinsky, CEO and Co-Founder Via Walbrook PR
Dr. Daniel Mahony, Chairman
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Limited Tel: 020 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen / Phillip Mob: 07980 541 893 / 0 7748 651 727
Marriage / 07867 984 082
About Trellus Health plc ( www.trellushealth.com )
Trellus Health (LSE: TRLS) is the first resilience based digital
health company focused on the intersection of chronic illness and
mental health. Trellus Health integrates its proprietary
resilience-based methodology with the technology, tools and team to
deliver a whole-person technology-enhanced experience that results
in relieving disease burden, building self-management skills and
promoting individual health behaviors that enable thriving in the
face of a chronic condition. Through its TrellusElevate(TM)
connected health platform and companion App, the company addresses
both physical and behavioral health together, in context, to
improve outcomes and reduce healthcare costs across the healthcare
ecosystem.
The Company is initially focused on Inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis, and shortly Irritable Bowel
Syndrome ("IBS"), but, given the common struggles of
self-management, considers its approach to have potential utility
and demand across many chronic conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD
treated using the methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12
months following starting the program(2) .
The Company was founded by Mount Sinai faculty members Marla C.
Dubinsky, MD and Laurie Keefer, PhD, both with decades of combined
experience in IBD and psychogastroenterology, respectively. Trellus
Health's patent-pending GRITT(TM) resilience assessment and
personalized resilience training methodology was developed and
validated at the Mount Sinai Health System to build resilience and
wellness for improved outcomes at lower cost.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
1) Source:
https://www.cdc.gov/chronicdisease/about/costs/index.htm )
2) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
)
About the Trellus IBD program
Trellus Health is pioneering a scientifically validated,
personalized resilience-driven self-management solution for chronic
health conditions which addresses the intersection of chronic
illness with mental health, estimated to cost the US economy $3.7
trillion annually.(1) The Trellus approach transforms chronic
condition management and changes the lives of patients living with
debilitating, incurable conditions, initially focused on IBD,
including Crohn's Disease and ulcerative colitis, and shortly IBS,
but with potential utility and demand across many chronic
conditions.
The Trellus IBD program is a self-management solution driven by
personalized resilience training. The program empowers and enables
members to manage their condition by teaching them to set goals,
actively identify challenges and solve problems associated with
their condition, driving a change of health behavior to deliver
improved outcomes and health status at lower cost.
Patients with IBD face many challenges which are common across
many chronic conditions: the management of complex medication
regimens, dealing with symptoms and disability, monitoring physical
indicators, maintaining proper levels of nutrition, adjusting to
the psychological and social demands including difficult lifestyle
adjustments, as well as engaging in effective interactions with
health providers.
Trellus's personalized resilience-driven self-management
training programs are designed specifically for people looking to
overcome these challenges. The aim is to enable patients and their
physicians to achieve better quality patient outcomes at a lower
cost to health plans and employers, and the proprietary resilience
method has been proven to reduce unplanned hospitalizations by 94%
at the Mount Sinai IBD Center, New York, NY.(2)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRMZGMZMZVGFZZ
(END) Dow Jones Newswires
February 13, 2023 02:00 ET (07:00 GMT)
Trellus Health (LSE:TRLS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Trellus Health (LSE:TRLS)
Historical Stock Chart
From Dec 2023 to Dec 2024
